Th17 cell inhibition in a costimulation blockade-based regimen for vascularized composite allotransplantation using a nonhuman primate model.
Th17 cells
nonhuman primates
vascular composite allograft
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
17
01
2020
revised:
11
02
2020
accepted:
31
03
2020
pubmed:
12
4
2020
medline:
25
6
2021
entrez:
12
4
2020
Statut:
ppublish
Résumé
Vascularized composite allotransplantation (VCA) is challenged by the morbidity of immunosuppression required to prevent rejection. The use of highly specific biologics has not been well explored in VCA. Given that psoriasis is T-cell mediated, as is rejection of skin-containing VCAs, we sought to assess the role of ustekinumab and secukinumab, which are approved to treat psoriasis by inhibiting Th17 cells. We combined these agents with belatacept and steroids in a VCA nonhuman primate model. Group I consisted of belatacept and steroids, group II was belatacept, ustekinumab with steroid taper, and group III was belatacept, secukinumab with steroid taper. Three animals were transplanted in each group. In group I, the mean graft survival time until the first sign of rejection was 10 days whereas in group II and III it was 10.33 and 11 days, respectively. The immunohistochemistry analysis showed that the number of IL-17a
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1294-1301Subventions
Organisme : Department of Defense
ID : W81XWH1320055
Commentaires et corrections
Type : CommentIn
Informations de copyright
2020 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
Références
Kollar B, Pomahac B, Riella LV. Novel immunological and clinical insights in vascularized composite allotransplantation. Curr Opin Organ Transplant 2019; 24: 42.
Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012; 181: 8.
Adams AB, Goldstein J, Garrett C, et al. Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function. Am J Transplant 2017; 17: 2922.
Kirk AD, Guasch A, Xu H, et al. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. Am J Transplant 2014; 14: 1142.
Freitas AM, Samy KP, Farris AB, et al. Studies introducing costimulation blockade for vascularized composite allografts in nonhuman primates. Am J Transplant 2015; 15: 2240.
Grahammer J, Weissenbacher A, Zelger BG, et al. Benefits and limitations of belatacept in 4 hand-transplanted patients. Am J Transplant 2017; 17: 3228.
Lo DJ, Anderson DJ, Weaver TA, et al. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 2013; 13: 320.
Muduma G, Hart WM, Patel S, Odeyemi AO. Indirect treatment comparison of belatacept versus tacrolimus from a systematic review of immunosuppressive therapies for kidney transplant patients. Curr Med Res Opin 2016; 32: 1065.
Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med 2009; 15: 746.
Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 2011; 11: 2523.
Cendales LLM, Bartlett S, Cheeseman J, et al. Skin as a harbinger of rejection of underlying structures in vascularized composite allografts: concordance or discordance? Am J Transplant 2016; 16(suppl 3): 433.
Cendales LC, Xu H, Bacher J, Eckhaus MA, Kleiner DE, Kirk AD. Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation 2005; 80: 1447.
Cendales LC, Kanitakis J, Schneeberger S, et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant 2008; 8: 1396.
Page EK, Page AJ, Kwun J, et al. Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques. Am J Transplant 2012; 12: 2395.
Kwun J, Page E, Hong JJ, et al. Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model. Am J Transplant 2015; 15: 815.
Cherikh WS, Cendales LC, Wholley CL, et al. Vascularized composite allotransplantation in the United States: a descriptive analysis of the Organ Procurement and Transplantation Network Data. Am J Transplant 2019; 19: 865.
Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21: 1587.
Espinosa J, Herr F, Tharp G, et al. CD57(+) CD4 T cells underlie belatacept-resistant allograft rejection. Am J Transplant 2016; 16: 1102.
Cortes-Cerisuelo M, Laurie SJ, Mathews DV, et al. Increased pretransplant frequency of CD28(+) CD4(+) TEM predicts belatacept-resistant rejection in human renal transplant recipients. Am J Transplant 2017; 17: 2350.
Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443.
Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6(5 Pt 1): 876.
Cendales L, Bray R, Gebel H, et al. Tacrolimus to belatacept conversion following hand transplantation: a case report. Am J Transplant 2015; 15: 2250.
Cendales LC, Ruch DS, Cardones AR, et al. De novo belatacept in clinical vascularized composite allotransplantation. Am J Transplant 2018; 18: 1804.
Liu XK, Clements JL, Gaffen SL. Signaling through the murine T cell receptor induces IL-17 production in the absence of costimulation, IL-23 or dendritic cells. Mol Cells 2005; 20: 339.
Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015; 373: 2534.
Benichou G, Gonzalez B, Marino J, Ayasoufi K, Valujskikh A. Role of memory T cells in allograft rejection and tolerance. Front Immunol 2017; 8: 170.
Krummey SM, Cheeseman JA, Conger JA, et al. High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept. Am J Transplant 2014; 14: 607.
Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood 2013; 121: 2402.
Issa F, Wood KJ. The potential role for regulatory T-cell therapy in vascularized composite allograft transplantation. Curr Opin Organ Transplant 2014; 19: 558.
Pilat N, Wiletel M, Weijler AM, et al. Treg-mediated prolonged survival of skin allografts without immunosuppression. Proc Natl Acad Sci USA 2019; 116: 13508.